The effect of the combination treatment with the GHRH agonist JI-34 + DOX on viability and apoptosis (A), calcein retention (B), and the expression of bFGF, TGFβ, and the tumor suppressor p53 (C), in vitro. For conditions see Materials and Methods and Results. *P < 0.05 vs. control. DOX, doxorubicin; FGFb, fibroblast growth factor basic; TGFβ, transforming growth factor β. *P < 0.05 vs. control, +P < 0.05 vs. DOX.